The long-term objectives of the proposed research project are to (1) enhance program participation and (2) improve the vocational outcome of persons with work disability due to arthritis and related musculoskeletal disorders (ARMD), who are actively seeking vocational rehabilitation services. It is hypothesized that persons with work disability due to ARMD seeking vocational rehabilitation (VR) services, who are exposed to an """"""""Agency Access Intervention"""""""", are more likely to gain entrance to the VR system and be determined eligible for services than are similar persons not exposed to the intervention. Further, it is hypothesized that persons with work disability due to ARMD who are determined to be eligible for VR services, and, who are exposed to an """"""""Agency Enhancement Intervention"""""""" during the provision of services are more likely to become and remain employed, upon completion of the VR program, than are similar persons not exposed to the intervention. The research design is a randomized, controlled, field experiment comparing the vocational outcomes of the group receiving the two-part intervention to those not receiving the intervention, and it allows evaluation of each component of the intervention separately. The intervention consists of training sessions to help prospective VR clients with ARMD successfully enter and complete the VR program, and training sessions for a randomly selected group of VR professionals to help them serve VR clients with ARMD more effectively. If this intervention strategy proves capable of significantly increasing (a) VR utilization rates, (b) post-service employment rates, and (c) duration of post-service employment in a previously underserved group with historically poor VR outcomes, it could have significant role in reducing the immense impact, nationally, of work disability due to arthritis and musculoskeletal disorders.

Project Start
2000-01-01
Project End
2000-12-31
Budget Start
Budget End
Support Year
23
Fiscal Year
2000
Total Cost
$116,317
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Wang, Hui; Rayburn, Elizabeth R; Wang, Wei et al. (2006) Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther 5:1585-92
Wang, Hui; Rayburn, Elizabeth R; Wang, Wei et al. (2006) Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther 5:2106-14

Showing the most recent 10 out of 145 publications